Trevi Therapeutics Inc
$ 13.70
2.62%
03 Dec - close price
- Market Cap 1,756,753,000 USD
- Current Price $ 13.70
- High / Low $ 13.93 / 13.08
- Stock P/E N/A
- Book Value 1.48
- EPS -0.37
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -0.37 %
- 52 Week High 13.93
- 52 Week Low 2.36
About
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in New Haven, Connecticut, focused on developing innovative therapies for patients suffering from serious neurology-mediated conditions. The company's lead product candidate, Haduvio, addresses significant unmet medical needs and is currently in clinical trials, reflecting Trevi's commitment to advancing its therapeutic pipeline. Leveraging its expertise in drug development and a strategic focus on commercialization opportunities, Trevi Therapeutics is well-positioned to deliver impactful solutions in the neurology sector, potentially transforming the treatment landscape for affected patients.
Analyst Target Price
$21.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-07 | 2025-05-05 | 2025-03-18 | 2024-11-06 | 2024-08-08 | 2024-05-07 | 2024-03-20 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-16 |
| Reported EPS | -0.08 | -0.09 | -0.09 | -0.11 | -0.13 | -0.12 | -0.11 | -0.08 | -0.08 | -0.07 | -0.06 | -0.06 |
| Estimated EPS | -0.1 | -0.1 | -0.09 | -0.1171 | -0.12 | -0.11 | -0.09 | -0.09 | -0.09 | -0.08 | -0.07 | -0.1 |
| Surprise | 0.02 | 0.01 | 0 | 0.0071 | -0.01 | -0.01 | -0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.04 |
| Surprise Percentage | 20% | 10% | 0% | 6.0632% | -8.3333% | -9.0909% | -22.2222% | 11.1111% | 11.1111% | 12.5% | 14.2857% | 40% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TRVI
2025-10-21 10:32:29
Trevi Therapeutics announced the acceptance of two abstracts for presentation at the CHEST 2025 Annual Meeting, featuring results from their Phase 2b CORAL and Phase 2a RIVER trials. The presentations will cover key efficacy and safety results of nalbuphine ER for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and patient-reported outcomes for refractory chronic cough (RCC). This highlights the company's progress in developing Haduvio™ (oral nalbuphine extended-release) for these conditions with high unmet medical needs.
2025-10-21 10:32:29
Trevi Therapeutics announced that data from its Phase 2a RIVER trial, evaluating Haduvio™ (oral nalbuphine ER) for refractory chronic cough (RCC), will be presented in two poster sessions at the European Respiratory Society (ERS) Congress 2025. The posters will detail the efficacy and safety of nalbuphine extended-release and a responder analysis from the trial. This highlights Haduvio's potential as an investigational therapy for RCC, a condition with significant unmet medical need.
2025-10-16 16:59:48
Vontobel Holding Ltd. has trimmed its stake in Trevi Therapeutics, Inc. while other hedge funds have adjusted their positions in the company. Several analysts have issued "buy" or "overweight" ratings with target price adjustments for Trevi Therapeutics. The article also provides an overview of Trevi Therapeutics, a clinical-stage biopharmaceutical company focusing on therapy for chronic cough conditions.
2025-10-14 17:12:42
This article reports that Trevi Therapeutics stock reached a new 52-week high of $10.16 USD. The content also includes an alert for Q3 earnings and information on an application error related to the website loading.
2025-10-14 16:54:00
The article reports that Trevi Therapeutics stock reached a 52-week high, trading at 10.16 USD. This information was provided by Investing.com. It appears to be a brief market update regarding the company's stock performance.
2024-12-16 07:36:00
Trevi Therapeutics, Inc. announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at $4.00 per share, raising $50 million in gross proceeds. The financing included participation from new and existing investors and is expected to close on December 17, 2024. The company plans to use the proceeds for general corporate purposes, including the development of Haduvio™ for chronic cough in IPF and RCC.
